Reduced Neutralization of SARS-CoV-2 B.1.617 by Vaccine and Convalescent Serum

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

Citing Articles

Mutational pressure promotes release of public CD8 T cell epitopes by proteasome from SARS-CoV-2 RBD of Omicron and its current lineages.

Kudriaeva A, Butenko I, Saratov G, Ri M, Mokrushina Y, Bondarev A iScience. 2025; 28(3):111873.

PMID: 40060909 PMC: 11889684. DOI: 10.1016/j.isci.2025.111873.

SARS-CoV-2 evolution on a dynamic immune landscape.

Raharinirina N, Gubela N, Bornigen D, Smith M, Oh D, Budt M Nature. 2025; 639(8053):196-204.

PMID: 39880955 PMC: 11882442. DOI: 10.1038/s41586-024-08477-8.

Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.

Hu H, Leng C, Shu Y, Peng L, Wu F, Liu J J Virol. 2025; 99(2):e0130724.

PMID: 39772622 PMC: 11852929. DOI: 10.1128/jvi.01307-24.

Case-only analysis of routine surveillance data: detection of increased vaccine breakthrough infections with SARS-CoV-2 variants in Europe.

Brown J, Brown J, Mook P, Vanhaverbeke M, Gimma A, Hagan J Epidemiol Infect. 2025; 153:e16.

PMID: 39757926 PMC: 11748014. DOI: 10.1017/S0950268824001833.

Structural Immunology of SARS-CoV-2.

Yuan M, Wilson I Immunol Rev. 2024; 329(1):e13431.

PMID: 39731211 PMC: 11727448. DOI: 10.1111/imr.13431.

References

Di Genova C, Sampson A, Scott S, Cantoni D, Mayora-Neto M, Bentley E . Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes. Bio Protoc. 2021; 11(21):e4236. PMC: 8595416. DOI: 10.21769/BioProtoc.4236. View

Smith D, Lapedes A, de Jong J, Bestebroer T, Rimmelzwaan G, Osterhaus A . Mapping the antigenic and genetic evolution of influenza virus. Science. 2004; 305(5682):371-6. DOI: 10.1126/science.1097211. View

Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M . Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021; 29(5):819-833.e7. PMC: 7953435. DOI: 10.1016/j.chom.2021.03.005. View

Krissinel E, Henrick K . Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007; 372(3):774-97. DOI: 10.1016/j.jmb.2007.05.022. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Winter G, Waterman D, Parkhurst J, Brewster A, Gildea R, Gerstel M . DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol. 2018; 74(Pt 2):85-97. PMC: 5947772. DOI: 10.1107/S2059798317017235. View

Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer A, Ginn H . Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184(11):2939-2954.e9. PMC: 8008340. DOI: 10.1016/j.cell.2021.03.055. View

Yuan M, Liu H, Wu N, Lee C, Zhu X, Zhao F . Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020; 369(6507):1119-1123. PMC: 7402627. DOI: 10.1126/science.abd2321. View

Ginn H . Pre-clustering data sets using cluster4x improves the signal-to-noise ratio of high-throughput crystallography drug-screening analysis. Acta Crystallogr D Struct Biol. 2020; 76(Pt 11):1134-1144. PMC: 7604910. DOI: 10.1107/S2059798320012619. View

10.

. An integrated national scale SARS-CoV-2 genomic surveillance network. Lancet Microbe. 2020; 1(3):e99-e100. PMC: 7266609. DOI: 10.1016/S2666-5247(20)30054-9. View

11.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

12.

Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R . Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust. 2020; 212(10):459-462. PMC: 7228321. DOI: 10.5694/mja2.50569. View

13.

Deng X, Garcia-Knight M, Khalid M, Servellita V, Wang C, Morris M . Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13):3426-3437.e8. PMC: 8057738. DOI: 10.1016/j.cell.2021.04.025. View

14.

Seemann T, Lane C, Sherry N, Duchene S, Goncalves da Silva A, Caly L . Tracking the COVID-19 pandemic in Australia using genomics. Nat Commun. 2020; 11(1):4376. PMC: 7462846. DOI: 10.1038/s41467-020-18314-x. View

15.

McCallum M, Bassi J, De Marco A, Chen A, Walls A, di Iulio J . SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021; 373(6555):648-654. PMC: 9835956. DOI: 10.1126/science.abi7994. View

16.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

17.

Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A . Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell. 2020; 184(1):64-75.e11. PMC: 7674007. DOI: 10.1016/j.cell.2020.11.020. View

18.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

19.

Aricescu A, Lu W, Jones E . A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006; 62(Pt 10):1243-50. DOI: 10.1107/S0907444906029799. View

20.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View